Anti-Lipoprotein Lipase Antibody as a Useful Marker for Plaque Vulnerability in Patients with Stable Angina

Area of Science:

• Cardiovascular Medicine
• Immunology
• Atherosclerosis Research

Background:

• Identifying vulnerable plaque in coronary artery disease (CAD) is critical for prognosis and treatment.
• Low anti-apolipoprotein B-100 autoantibody (anti-apoB-100 Ab) levels are linked to unstable plaques in male CAD patients.
• Lipoprotein lipase (LPL) is involved in triglyceride metabolism and atherosclerosis.

Purpose of the Study:

• To investigate the association between autoantibodies against lipoprotein lipase (anti-LPL Ab) and coronary plaque characteristics in male CAD patients.
• To determine if anti-LPL Ab levels can serve as a marker for plaque instability.
• To assess the combined utility of anti-LPL Ab and anti-apoB-100 Ab levels in identifying high-risk CAD patients.

Main Methods:

• Serum anti-LPL Ab levels were measured using a homemade enzyme-linked immunosorbent assay in 80 male CAD patients.
• Coronary plaque properties were assessed using iMAP®-intravascular ultrasound.
• Patients were stratified based on anti-LPL Ab levels, particularly those with low anti-apoB-100 Ab.

Main Results:

• Serum anti-LPL Ab levels did not correlate with plaque burden.
• Anti-LPL Ab levels showed significant negative correlation with fibrotic plaques and positive correlation with necrotic plaques.
• CAD patients with low anti-apoB-100 Ab and high anti-LPL Ab levels had more necrotic plaques, fewer fibrotic plaques, and higher remnant-like lipoprotein particle levels.

Conclusions:

• Serum anti-LPL Ab levels are a potential marker for coronary plaque instability in CAD.
• The combination of anti-LPL Ab and anti-apoB-100 Ab levels can enhance the identification of high-risk CAD patients.
• Further research may elucidate the role of anti-LPL Ab in atherosclerosis progression and plaque vulnerability.